Lumizyme® (Alglucosidase Alfa) - CAM 963HB

Background

FDA-Approved Indication: Lumizyme is a recombinant human acid alpha-glucosidase (GAA) enzyme replacement therapy indicated for patients with Pompe disease (glycogen storage disease type II). Pompe disease is caused by a deficiency of lysosomal acid alpha-glucosidase resulting in lysosomal glycogen accumulation in cardiac, skeletal, and respiratory muscle tissues.

Policy

Initial Authorization Criteria

Infantile-Onset Pompe Disease (IOPD)

Lumizyme may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of infantile-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) confirmed by one of the following:

  • Enzyme Assay: Absence or deficiency (less than 1% of the laboratory-specific normal mean) of GAA enzyme activity in lymphocytes, fibroblasts, or muscle tissue as demonstrated by an enzymatic assay
  • Genetic Testing: Molecular genetic testing confirms pathogenic mutation(s) in the GAA gene

2. Presence of clinical signs and symptoms of Pompe disease examples include:

  • Hypertrophic cardiomyopathy/cardiomegaly
  • Hypotonia ("floppy infant")
  • Muscle weakness
  • Feeding difficulties
  • Failure to thrive
  • Respiratory insufficiency
  • Developmental delay

3. Patient is less than or equal to 12 months of age at disease onset

Authorization Duration: 6 months

Late-Onset Pompe Disease (LOPD)

Lumizyme may be considered medically necessary when all of the following criteria are met:

1. Diagnosis of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) confirmed by one of the following:

  • Enzyme Assay: Deficiency of GAA enzyme activity (less than 40% of the laboratory-specific normal mean) in lymphocytes, fibroblasts, or muscle tissue as demonstrated by an enzymatic assay
  • Genetic Testing: Molecular genetic testing confirms pathogenic mutation(s) in the GAA gene

2. Presence of clinical signs and symptoms of Pompe disease examples include:

  • Skeletal muscle weakness
  • Progressive proximal muscle weakness
  • Respiratory muscle weakness
  • Respiratory distress
  • Reduced forced vital capacity (FVC)
  • Exercise intolerance
  • Difficulty ambulating
  • Fatigue
  • Sleep-disordered breathing

3. Patient is 1 year of age or older

Authorization Duration: 6 months

Reauthorization Criteria

Lumizyme may be reauthorized when all of the following criteria are met:

1. Diagnosis of Pompe disease remains valid

2. Documentation of positive clinical response or disease stabilization compared with pretreatment baseline, demonstrated by one or more of the following:

Infantile-Onset Pompe Disease

  • Improved or stabilized cardiac function
  • Improvement in left ventricular mass index
  • Improvement in growth and developmental milestones
  • Improved survival
  • Reduced ventilatory support requirements
  • Preservation or improvement of motor function

Late-Onset Pompe Disease

  • Stabilization or improvement in motor function
  • Stabilization or improvement in muscle strength
  • Stabilization or improvement in pulmonary function testing (e.g., FVC)
  • Improvement or maintenance of ambulation status
  • Improvement in endurance testing (e.g., 6-minute walk test)
  • Reduced need for respiratory support
  • Slowed disease progression

3. Therapy is prescribed by or in consultation with a physician experienced in the treatment of inherited metabolic disorders, neuromuscular disorders, or Pompe disease

Authorization Duration: 12 months

References

  1. Lumizyme® (alglucosidase alfa) Prescribing Information. Genzyme Corporation, a Sanofi Company. Current prescribing information.
  2. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant Human Acid Alpha-Glucosidase: Major Clinical Benefits in Infantile-Onset Pompe Disease. Neurology. 2007;68(2):99-109.
  3. Van der Ploeg AT, Clemens PR, Corzo D, et al. A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe Disease. New England Journal of Medicine. 2010;362(15):1396-1406.
  4. Kishnani PS, Steiner RD, Bali D, et al. Pompe Disease Diagnosis and Management Guideline. Genetics in Medicine. 2006;8(5):267-288.
  5. Cupler EJ, Berger KI, Leshner RT, et al. Consensus Treatment Recommendations for Late-Onset Pompe Disease. Muscle & Nerve. 2012;45(3):319-333.
  6. American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). Clinical guidance for Pompe disease management.
  7. GeneReviews®. Pompe Disease.
  8. National Organization for Rare Disorders (NORD). Pompe Disease.

Coding Section

Code

Number

Description

CPT

96365

Intravenous infusion therapy prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

 

96366

Each additional hour. (List separately in addition to primary procedure code, 96365)

HCPCS

J0221

Injection, alglucosidase alfa (Lumizyme), 10 mg

ICD-10

E74.02

Pompe Disease

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2026 Forward

10/01/2026

New Policy

Complementary Content
${loading}